State of Wyoming Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX

Posted by Brenda Bartman on Aug 19th, 2026

State of Wyoming acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 9,676 shares of the company’s stock, valued at approximately $362,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of CRNX. GW&K Investment Management LLC increased its holdings in Crinetics Pharmaceuticals by 73.6% in the 4th quarter. GW&K Investment Management LLC now owns 1,476,325 shares of the company’s stock worth $68,723,000 after buying an additional 625,779 shares during the period. UBS Group AG lifted its stake in Crinetics Pharmaceuticals by 122.7% during the 4th quarter. UBS Group AG now owns 908,192 shares of the company’s stock valued at $42,276,000 after acquiring an additional 500,470 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Crinetics Pharmaceuticals by 5.3% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 408,312 shares of the company’s stock valued at $19,007,000 after acquiring an additional 20,387 shares during the last quarter. Sector Gamma AS purchased a new stake in shares of Crinetics Pharmaceuticals in the 4th quarter valued at $5,353,000. Finally, Glenmede Trust Co. NA increased its stake in shares of Crinetics Pharmaceuticals by 72.6% in the first quarter. Glenmede Trust Co. NA now owns 29,245 shares of the company’s stock worth $1,062,000 after acquiring an additional 12,301 shares during the period. Institutional investors and hedge funds own 98.51% of the company’s stock.

Wall Street Analyst Weigh In

CRNX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a report on Friday, July 17th. Piper Sandler lowered shares of Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. TD Cowen downgraded Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 8th. Wall Street Zen upgraded Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Finally, Evercore cut Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Crinetics Pharmaceuticals has an average rating of “Hold” and a consensus target price of $81.00.

View Our Latest Stock Report on CRNX

Crinetics Pharmaceuticals Stock Down 0.0%

NASDAQ:CRNX opened at $84.72 on Wednesday. Crinetics Pharmaceuticals, Inc. has a 52 week low of $28.73 and a 52 week high of $84.80. The stock’s 50-day moving average price is $66.01 and its 200-day moving average price is $48.69. The stock has a market capitalization of $8.99 billion, a PE ratio of -16.81 and a beta of 0.12.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.04. The company had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $14.84 million. Crinetics Pharmaceuticals had a negative return on equity of 44.22% and a negative net margin of 1,189.88%.Crinetics Pharmaceuticals’s quarterly revenue was up 2336.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.23) EPS. Sell-side analysts expect that Crinetics Pharmaceuticals, Inc. will post -4.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Stephanie Okey sold 6,900 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total transaction of $246,123.00. Following the transaction, the director owned 6,400 shares in the company, valued at $228,288. This trade represents a 51.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the sale, the director directly owned 19,225 shares in the company, valued at $769,000. This represents a 13.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.80% of the company’s stock.

Crinetics Pharmaceuticals Profile

(Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.